Delivering Injectable Drugs Orally

 

Chiasma is developing oral formulations of injectable drugs using its proprietary drug development technology. This allows therapies that would normally break down in the stomach to reach the small intestine, where they can be absorbed. At the end of June, the company won approval for Mycapssa, the first and only oral therapy to treat acromegaly, a rare condition in which the overproduction of growth hormone can lead to serious health conditions. It was the first drug approved using the company’s drug delivery technology. We spoke to Raj Kannan, CEO of Chiasma, about the company’s recently approved therapy for acromegaly, the company’s drug delivery technology, and the value of having oral alternatives to injectable therapies.